Anaritide

Drug Profile

Anaritide

Alternative Names: Auriculin; hANP (102-126); WY 47663

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scios
  • Developer Genentech; Scios
  • Class Antihypertensives; Anxiolytics; Heart failure therapies; Hormones; Natriuretic peptides
  • Mechanism of Action Atrial peptide agonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Heart failure; Hypertension; Renal failure

Most Recent Events

  • 06 Nov 1997 Discontinued-Clinical for Heart failure in USA (IV)
  • 06 Nov 1997 Discontinued-Clinical for Hypertension in European Union (IV)
  • 06 Nov 1997 Discontinued-Clinical for Hypertension in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top